Actively Recruiting
TCF-001 TRACK (Target Rare Cancer Knowledge) Study
Led by TargetCancer Foundation · Updated on 2024-08-09
400
Participants Needed
1
Research Sites
269 weeks
Total Duration
On this page
Sponsors
T
TargetCancer Foundation
Lead Sponsor
F
Foundation Medicine
Collaborating Sponsor
AI-Summary
What this Trial Is About
This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.
CONDITIONS
Official Title
TCF-001 TRACK (Target Rare Cancer Knowledge) Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed and dated informed consent form provided.
- Willingness to comply with all study-related blood draws and assessments throughout the study.
- Age 18 years or older at time of consent.
- Diagnosis of a rare solid tumor or lymphoma with evaluable disease at baseline.
- May have had prior qualifying comprehensive genomic profiling within 18 months before baseline visit.
- Willingness to provide archived and/or newly collected tissue from standard care and blood samples for genomic profiling.
- Archival tissue samples must have been collected within 18 months of baseline visit.
- Willingness to provide clinical and medical information as required.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
- Ability to read, write, and communicate in English.
- Ability to review and sign informed consent online or in physician's office.
- Residence within the United States.
You will not qualify if you...
- Unable to provide informed consent.
- Age 17 years or younger.
- Unable to comply with study procedures.
- Presence of uncontrolled illness, including psychiatric or social issues impairing compliance.
- Active malignancy requiring treatment within 1 year of enrollment, as judged by treating physician.
- Pregnancy or breastfeeding.
- Any other criteria deemed exclusionary by the treating physician.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
TargetCancer Foundation
Cambridge, Massachusetts, United States, 02139
Actively Recruiting
Research Team
M
Mary Oster
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
FACTORIAL
Primary Purpose
DIAGNOSTIC
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here